TY - JOUR
AR - COR-2020-7-109
TI - Water-soluble SCR7 Can Abrogate DNA End Joining and Induce Cancer Cell Death
AU - Ujjayinee , Ray
AU - Anjana , Elizabeth Jose
AU - Rohini , Suresh
AU - Uthara , Kaloor
AU - Hassan A. , Swarup
AU - Mridula , Nambiar
AU - Sathees C., Raghavan
JO - Clinical Oncology and Research
PY - 2020
DA - Thu 16, Jul 2020
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2020.07.09
UR - https://www.sciencerepository.org/water-soluble-scr7-can-abrogate-dna-end-joining-and-induce_COR-2020-7-109 
KW - NHEJ inhibitor, DSB repair, nonhomologous end joining, ligase IV, apoptosis, cancer therapy
AB - Small molecule inhibitors targeting DNA repair pathways in cancer cells is a novel and promising approach
in cancer therapy, which can improve current therapeutic regimen. Although various attempts have been
made for designing inhibitors against DNA damage response and repair proteins, reports on
Nonhomologous End Joining (NHEJ) inhibitors are limited. Of the several chemical moieties identified,
SCR7 and its oxidized form are novel and potent DNA Ligase IV inhibitors involved in the abrogation of
DNA end joining thereby leading to cell death. In the present study, we have synthesized sodium salt of
SCR7 to generate a water-soluble version of the molecule, referred to as water-soluble SCR7 (WS-SCR7).
WS-SCR7 inhibits NHEJ in Ligase IV dependent manner, with a subtle effect on Ligase III at higher
concentration. No effect on Ligase I mediated joining was observed. WS-SCR7 shows cytotoxicity in cancer
cell lines, leading to induction of apoptosis in a dose-dependent manner.